Mydecine Innovations Group Inc. is a publicly traded, pre-revenue biopharmaceutical company that began operations in North America and Europe in early 2020. Mydecine was founded to increase physicians' access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions such as pain, anxiety, depression, addiction, and PTSD, along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective, and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (AI). Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations.

Each Warrant shall entitle each Warrantholder thereof, upon exercise at any time after the Issue Date and prior to the Expiry Time, to acquire one Common Share upon payment of the Exercise Price of $0.70.

See the Warrant Indenture for full details.

The Exchange has determined that the Issuer has not met the continued listing requirements as set out in CSE Policy 2, Appendix A, section 2.9.

Pursuant to Policy 6 section 2.4, the Issuer may not rely on confidential price protection, nor may the Issuer complete a financing without prior Exchange approval.

In accordance with Policy 3, section 5.1, the .X extension is added to the listed securities of Issuers that the Exchange has deemed to be inactive.

Pangea Natural Foods Inc. is a food manufacturing company focused on manufacturing and distributing high quality food products across North America.